Clinical Scorecard: Current Developments and Future Perspectives on Multivariate Risk Assessment Tools Incorporating MRI for Personalized Biopsy Decisions in Prostate Cancer Diagnosis

At a Glance

Key Highlights

• Systematic transrectal ultrasound-guided biopsy is associated with rising antibiotic-resistant infections and detection of indolent PCa.
• mpMRI has high negative predictive value and is increasingly used as a triage test to reduce unnecessary biopsies.
• Multivariate risk prediction models incorporating mpMRI improve diagnostic accuracy and can reduce unnecessary biopsies while maintaining detection of clinically significant PCa.

Guideline-Based Recommendations

Diagnosis

• Use validated multivariate risk prediction models to estimate risk of clinically significant PCa before biopsy.
• Incorporate mpMRI as an upfront or prebiopsy diagnostic test, especially in biopsy-naïve men and men with prior negative biopsy but ongoing suspicion.
• mpMRI is indicated when systematic biopsy is considered, to improve diagnostic yield.

Management

• Consider deferring biopsy in men with no suspicious findings on mpMRI due to its high negative predictive value.
• Use risk thresholds (e.g., ≥10% risk of ISUP grade ≥2 PCa) from MRI-inclusive risk models to guide biopsy decisions and reduce unnecessary procedures.

Monitoring & Follow-up

• Monitor biopsy outcomes and adjust risk thresholds based on population prevalence and individual risk factors.
• Validate and recalibrate risk prediction models in local populations to optimize clinical utility.

Risks

• Systematic biopsy carries risk of septic complications, especially with rising antibiotic resistance.
• Risk of missing clinically significant PCa exists but is minimized by using combined mpMRI and multivariate risk models.
• Detection of clinically insignificant PCa can lead to overtreatment; risk models aim to reduce this.

Patient & Prescribing Data

Men undergoing evaluation for suspected prostate cancer, including biopsy-naïve and those with prior negative biopsy

Incorporation of mpMRI into risk prediction models increases AUC for detecting clinically significant PCa (ISUP grade ≥2) from approximately 0.72–0.81 to 0.83–0.84, enabling reduction of unnecessary biopsies by 14–17% at a 10% risk threshold while missing only a small proportion (3–6%) of significant cancers.

Clinical Best Practices

• Employ multivariate risk calculators that include PSA, DRE, age, prostate volume, prior biopsy status, and mpMRI PI-RADS scores for individualized risk assessment.
• Use mpMRI as a triage tool to decide on biopsy necessity, especially in men with prior negative biopsy or low suspicion on clinical parameters.
• Apply decision curve analysis and net benefit evaluation to select appropriate risk thresholds for biopsy indication.
• Validate risk prediction models externally and recalibrate for local patient populations to maintain accuracy.
• Balance the benefits of reducing unnecessary biopsies against the risk of missing clinically significant cancers.

References

• European Randomized Study of Screening for Prostate Cancer Risk Calculators (ERSPC-RC)
• Multiparametric MRI in Prostate Cancer Diagnosis
• Guidelines on Prostate Cancer Diagnosis and Management
• Mehralivand et al. MRI Risk Prediction Model Study
• Radtke et al. Multivariate Prediction Modeling